Legend: drug field target field enzyme field
| Version | 2.5 | ||||||||
| Creation Date | 2005-06-13 13:24:05 | ||||||||
| Update Date | 2009-04-16 16:47:34 | ||||||||
| Primary Accession Number | DB00258 | ||||||||
| Secondary Accession Number |
|
||||||||
| Name | Calcium Acetate | ||||||||
| Drug Type |
|
||||||||
| Description | The chemical compound calcium acetate is the calcium salt of acetic acid. An older name is acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form. [Wikipedia] | ||||||||
| Synonyms |
|
||||||||
| Brand Names |
|
||||||||
| Brand Mixtures |
|
||||||||
| Chemical IUPAC Name | calcium diacetate | ||||||||
| Chemical Formula | C4H6CaO4 | ||||||||
| Chemical Structure | |||||||||
| CAS Registry Number | 62-54-4 | ||||||||
| InChI Identifier | InChI=1/2C2H4O2.Ca/c2*1-2(3)4;/h2*1H3,(H,3,4);/q;;+2/p-2/f2C2H3O2.Ca/q2*-1;m | ||||||||
| InChI Key | VSGNNIFQASZAOI-BGXWZCFKCS | ||||||||
| KEGG Drug | D00931 ![]() |
||||||||
| KEGG Compound | Not Available | ||||||||
| PubChem Compound | 6116 ![]() |
||||||||
| PubChem Substance | 7847994 ![]() |
||||||||
| ChEBI ID | Not Available | ||||||||
| PharmGKB ID | PA448724 ![]() |
||||||||
| HET ID | Not Available | ||||||||
| GenBank ID | Not Available | ||||||||
| Drug ID Number [DIN] | 01982591 ![]() |
||||||||
| RxList Link | Not Available | ||||||||
| PDRhealth Link | Not Available | ||||||||
| Wikipedia Link | http://en.wikipedia.org/wiki/Calcium_Acetate ![]() |
||||||||
| FDA Label |
|
||||||||
| Material Safety Data Sheet (MSDS) | |||||||||
| Synthesis Reference | Not Available | ||||||||
| Average Molecular Weight | 158.1660 | ||||||||
| Monoisotopic Molecular Weight | 157.9892 | ||||||||
| State | Solid | ||||||||
| Melting Point | > 160 oC | ||||||||
| Experimental Water Solubility | Not Available Source: PhysProp | ||||||||
| Predicted Water Solubility | 1.47e+02 mg/mL Calculated using ALOGPS | ||||||||
| Experimental LogP/Hydrophobicity | Not Available Source: PhysProp | ||||||||
| Predicted LogP | 0.24 Calculated using ALOGPS | ||||||||
| Experimental LogS | Not Available | ||||||||
| Predicted LogS | -0.03 Calculated using ALOGPS | ||||||||
| Experimental Caco2 Permeability | Not Available | ||||||||
| pKa/Isoelectric Point | Not Available | ||||||||
| Mass Spectrum | Not Available | ||||||||
| MOL File | Show | Download ![]() |
||||||||
| SDF File | Show | Download ![]() |
||||||||
| PDB File | Show | Download ![]() |
||||||||
| 2D Structure | |||||||||
| 3D Structure | |||||||||
| Experimental PDB ID | Not Available | ||||||||
| Isomeric SMILES | [Ca++].CC([O-])=O.CC([O-])=O | ||||||||
| Canonical SMILES | [Ca++].CC([O-])=O.CC([O-])=O | ||||||||
| Drug Category |
|
||||||||
| ATC Codes | |||||||||
| AHFS Codes |
|
||||||||
| Indication | Used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease. | ||||||||
| Pharmacology | Patients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine. | ||||||||
| Mechanism of Action | Calcium acetate works by binding with the phosphate in the food you eat, so that it is eliminated from the body without being absorbed. | ||||||||
| Absorption | 40% is absorbed in the fasting state and approximately 30% is absorbed in the nonfasting state following oral administration. | ||||||||
| Toxicity | Oral, rat: LD50 = 4280 mg/kg. Symptoms of overdose include mild hypercalcemia (constipation; loss of appetite; nausea and vomiting), and severe hypercalcemia (confusion; full or partial loss of consciousness; incoherent speech). | ||||||||
| Protein Binding | Not Available | ||||||||
| Biotransformation | Not Available | ||||||||
| Half Life | Not Available | ||||||||
| Dosage Forms |
|
||||||||
| Patient Information | Not Available | ||||||||
| Contraindications | Show ![]() |
||||||||
| Interactions | Show ![]() |
||||||||
| Drug Interactions | Not Available | ||||||||
| Food Interactions | Not Available | ||||||||
| Pathways | Not Available | ||||||||
| General References | |||||||||
| Organisms Affected |
|
This project is supported by Genome Alberta & Genome Canada, a not-for-profit organization that is leading Canada's national genomics strategy with $600 million in funding from the federal government. This project is also supported in part by GenomeQuest, Inc., an enterprise genomic information company serving the life science community.